title: [The ocular hypotensive effect and safety of 0.2% brimonidine].
abstract: OBJECTIVE
  To study the ocular hypotensive efficacy and safety of 0.2% Brimonidine when used in chinese people.
  
  
  METHODS
  Using randominzed parallel group control study, 0.2% Brimonidine twice a day or 1% Carteolol twice a day was applied in patients with primary open angle glaucoma or ocular hypertension for three months.
  
  
  RESULTS
  The results showed that 0.2% Brimonidine and 1% Carteolol both have good ocular hypotensive efficacy. There was no significant difference between them. 0.2% Brimonidine did not produce significant changes in pupil size and heart rate. Change in blood pressure was not clinically significant. Six patients with 0.2% Brimonidine had drowsiness. Two patients had dry mouth. One patient had ocular burning.
  
  
  CONCLUSIONS
  Our results suggested that 0.2% Brimonidine would be a stable and effective antiglaucoma medicine with good tolerance. Thus, 0.2% Brimonidine should be the main choice of medical therapy for primary open angle glaucoma and ocular hepertension.
authors.affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China.
authors.forename: M
authors.initials: M
authors.lastname: Yu
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Ge
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000068438:Brimonidine Tartrate; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011810:Quinoxalines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000316:Adrenergic alpha-Agonists; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate